ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "registry"

  • Abstract Number: 0933 • ACR Convergence 2021

    Sustained Functional Remission in Axial Spondyloarthritis (axSpA): Which Are the Primary Outcomes That Should Be Targeted to Achieve This?

    Walter Maksymowych1, Robert Inman2, Louis Bessette3, Proton Rahman4, Emmanouil Rampakakis5, Odalis Asin-Milan6, Meagan Rachich6, Anne Marilise Marrache6 and Allen Lehman6, 1Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, 2University Health Network, Toronto, ON, Canada, 3Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, 4Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, 5JSS Medical Research, Montréal, QC, Canada, 6Janssen Inc., Toronto, ON, Canada

    Background/Purpose: A treat-to-target (T2T) strategy has been advocated for the management of axSpA although no consensus exists as to the most appropriate target or the…
  • Abstract Number: 0255 • ACR Convergence 2021

    Identification of Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

    Melissa Mannion1, Fenglong Xie1, Timothy Beukelman1, Jeffrey Curtis2 and , for the CARRA Registry Investigators3, 1University of Alabama at Birmingham, Birmingham, AL, 2Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 3CARRA, Durham, NC

    Background/Purpose: Recent treat to target recommendations for the treatment of juvenile idiopathic arthritis (JIA) recommend frequent evaluation and treatment intensification until the disease activity target…
  • Abstract Number: 1217 • ACR Convergence 2021

    Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada

    Mohammad Movahedi1, Denis Choquette2, Louis Coupal2, Angela Cesta3, Xiuying Li3, Edward Keystone4 and Claire Bombardier5, 1Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 2Institut de Rhumatologie de Montréal, Montréal, QC, Canada, 3Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, 4Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 5University of Toronto - Toronto, Toronto, ON, Canada

    Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as the first or an alternative option to biologic disease-…
  • Abstract Number: 0336 • ACR Convergence 2021

    The Incremental Clinical Utility of a Multianalyte Assay Panel with Cell-Bound Complement Activation Products versus a Traditional ANA Testing Strategy for the Diagnosis and Treatment of SLE

    Tyler O'Malley1, Fenglong Xie2, yujie Su2, cassie Clinton2, Debra J. Zack1, Jeffrey Curtis3 and John Wegener1, 1Exagen Inc., Vista, CA, 2University of Alabama at Birmingham, Birmingham, AL, 3Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The comparative clinical utility of various diagnostic tests to aid the differential diagnosis of SLE is unclear. We compare the outcomes of testing with…
  • Abstract Number: 1264 • ACR Convergence 2021

    Racial Differences in Chronic Glucocorticoid Use in Patients with SLE: A Cross Sectional Study

    James Sullivan1 and Emily Littlejohn2, 1Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH, 2Cleveland Clinic, Cleveland, OH

    Background/Purpose: Black patients with systemic lupus erythematosus (SLE) face higher rates of morbidity and mortality compared to White patients. Long-term glucocorticoid use has been associated…
  • Abstract Number: 0354 • ACR Convergence 2021

    A Cross-Sectional Study of Rheumatoid Arthritis Diagnoses in Patients with Systemic Lupus Erythematosus

    Kathryn Starzyk1, Gary Curhan2 and Julia Brault2, 1OM1, Inc, Boston, MA, 2OM1, Boston, MA

    Background/Purpose: Features of autoimmune conditions may coexist in individual patients, which may represent an overlapping single disease with features of both (i.e., ‘rhupus’), or the…
  • Abstract Number: 1364 • ACR Convergence 2021

    Autologous Hematopoietic Stem Cell (HSC) Transplantation for Systemic Sclerosis, North American Registry: Updated Outcomes and the Impact of CD34+ HSC Enrichment

    George Georges1, Keith Sullivan2, Dinesh Khanna3, Matthew Mei4, Maureen Mayes5, Dan Furst6, Mark Wener7, Suzanne Kafaja8, Gwynn Long2, Vaishali Sanchorawala9, Kareem Jamani10, Attaphol Pawarode3, Ashish Masurekar11, Brian Lam12, Richard Nash13, Marcin Trojanowski9, Chitra Hosing14, Philip Clements15, Tanya Helms2, Bernadette McLaughlin16, Linda Griffith17, Kyle Hebert18, Mary Eapen18, Jan Storek10 and Harold Atkins11, 1Fred Hutchison Cancer Research Center and University of Washington, Seattle, WA, 2Duke University School of Medicine, Durham, NC, 3University of Michigan, Ann Arbor, MI, 4City of Hope Comprehensive Cancer Center, Duarte, CA, 5Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, 6University of California Los Angeles, Los Angeles, CA, 7University of Washington, Seattle, WA, 8University of California Los Angeles Division of Rheumatology, Los Angeles, CA, 9Boston University School of Medicine, Boston, MA, 10University of Calgary, Calgary, AB, Canada, 11Ottawa Hospital Research Institute, Ottawa, ON, Canada, 12University of Texas McGovern Medical School, Houston, TX, 13Colorado Blood Cancer Institute, Denver, CO, 14University of Texas MD Anderson Cancer Center, Houston, TX, 15University of California Los Angeles School of Medicine, Department of Rhemumatology, Los Angeles, CA, 16Fred Hutchison Cancer Research Center, Seattle, WA, 17Division of Allergy Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, 18Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Autologous hematopoietic stem cell transplantation (AHSCT) is now established as a preferred standard of care treatment for patients with severe scleroderma with internal organ…
  • Abstract Number: 0372 • ACR Convergence 2021

    Impact of Gender and Age on Ankylosing Spondylitis Patient Profiles at Golimumab Initiation and 12-Month Outcomes

    Ariel Masetto1, Proton Rahman2, Michelle Teo3, Pauline Boulos4, Emmanouil Rampakakis5, Meagan Rachich6, Allen Lehman6, Francois Nantel7 and Odalis Asin-Milan6, 1Universite de Sherbrooke, Sherbrooke, QC, Canada, 2Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, 3Penticton Regional Hospital, Penticton, BC, Canada, 4., Hamilton, ON, Canada, 5JSS Medical Research, Montréal, QC, Canada, 6Janssen Inc., Toronto, ON, Canada, 7., Montréal, QC, Canada

    Background/Purpose: Gender and age have been previously identified as independent predictors of response to anti-TNFs. The aim of this analysis was to compare, between genders…
  • Abstract Number: 1442 • ACR Convergence 2021

    Effectiveness of Cycling JAKi Compared to Switching to bDMARD in Patients Who Failed a First JAKi in an International Collaboration of Registries of Rheumatoid Arthritis Patients (the JAK-pot Study)

    Manuel Pombo-Suarez1, Carlos Sanchez-Piedra2, Juan J Gomez-Reino3, Kim Lauper4, Nevsun Inanc5, Anja Strangfeld6, Doreen Huschek7, Karel Pavelka8, Eirik Kristianslund9, Tore Kvien10, Ziga Rotar11, Dan Nordström12, Denis Choquette13, Ori Elkayam14, Burkhard Leeb15, Maria José Santos16, Kimme Hyrich17, Lianne Kearsley-Fleet18, Catalin Codreanu19, Denis Monguin20, Delphine Courvoisier20 and Axel Finckh21, 1Rheumatology Service, Hospital Clinico Universitario, Santiago De Compostela, Santiago de Compostela, Spain, 2Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 3Hospital Clínico Universitario, Santiago de Compostela, Spain, 4Geneva University Hospitals, Geneve, Switzerland, 5Division of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 6Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 7Epidemiology and Health Services Research, German Rheumatism Research Center, Berlin, Germany, Berlin, Germany, 8Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 9Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 10Diakonhjemmet Hospital, Oslo, Norway, 11Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, 12Division of Internal Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland, 13Institut de Rhumatologie de Montréal, Montréal, QC, Canada, 14Tel Aviv Medical Center, Tel Aviv, Israel, 15Karl Landsteiner University for Health Sciences, Krems/Donau, Karl Landsteiner Institute for Clinical Rheumatology, Hollabrunn, Austria, 16Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, 17University of Manchester, Manchester, United Kingdom, 18Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 19Center of Rheumatic Diseases, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania, 20Division of Rheumatology, Geneva University Hospital, Geneva, Switzerland, 21University Hospital of Geneva, Geneve - Vesenaz, Switzerland

    Background/Purpose: With the arrival of new Janus kinase inhibitors (JAKi), with different JAK inhibition profiles, there is the possibility of using a second JAKi in…
  • Abstract Number: 0568 • ACR Convergence 2021

    Construction of the Veterans Affairs National Rheumatoid Arthritis Database (VANRAD)

    Amy Joseph1, Jodi Yanagida1, Xinliang Huang1, Prabha Ranganathan1, Melissa Laurie2, Hong Xian1 and Seth Eisen1, 1VA St. Louis Health Care System, St. Louis, MO, 2Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: The Department of Veterans Affairs (DVA) provides comprehensive medical care at minimal or no cost to 9 million veterans annually through 170 medical centers…
  • Abstract Number: 1624 • ACR Convergence 2021

    Patient-Reported Care Utilization, Socioeconomic Status, and Health Status Among Young Adults with JIA

    Emily Smitherman1, Rouba Chahine1, Nicole Bitencourt2, AKM Rahman1, Erica Lawson3 and Joyce Chang4, 1University of Alabama at Birmingham, Birmingham, AL, 2Loma Linda University Medical Center, Redlands, CA, 3University of California San Francisco, San Francisco, CA, 4Boston Children's Hospital, Brookline, MA

    Background/Purpose: Young adulthood is a vulnerable period for individuals with childhood-onset rheumatic diseases, especially the transition from pediatric to adult care. Our objective was to…
  • Abstract Number: 0658 • ACR Convergence 2021

    ACCORD: A Novel Rheumatology Transition Clinic Structure for Adolescent and Young Adult Patients with Childhood Onset Rheumatic Disease

    Rebecca Overbury1, Kelly Huynh2, Tracy Frech1, John Bohnsack1 and Aimee Hersh1, 1University of Utah, Salt Lake City, UT, 2Intermountain Health Care, Salt Lake City, UT

    Background/Purpose: The transition of health care from Pediatric to Adult providers for adolescents and young adults with childhood onset rheumatic disease continues to be associated…
  • Abstract Number: 1779 • ACR Convergence 2021

    A Comparison of Quality of Life Outcomes Between Psoriatic Arthritis and Psoriasis Patients: Data from the Brigham Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)

    Nancy Shadick1, Kumiko Schnock2, Vivi Feather2, Jing Cui3, Gabriela Maica2, Alexa Marshall2, Wynona Francis2, Muibat Yussuff2, Lourdes Maria Perez Chada2, Michael E. Weinblatt2 and Joseph Merola4, 1Brigham & Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham Women's Hospital, Boston, MA, 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: To report the demographics, clinical characteristics, and differential impacts on quality of life measures among participants in the Psoriasis (PsO) and Psoriatic Arthritis (PsA)…
  • Abstract Number: 0766 • ACR Convergence 2021

    Baseline Characteristics and Patient Reported Outcomes from a Juvenile Dermatomyositis Registry Inception Cohort

    Jessica Neely1, Kaveh Ardalan2, Adam Huber3 and Susan Kim4, 1University of California San Francisco, San Francisco, CA, 2Duke University Medical Center, Durham, NC, 3Dalhousie University, Halifax, NS, Canada, 4UCSF Benioff Children's Hospital, San Francisco, CA

    Background/Purpose: Juvenile dermatomyositis (JDM), the most common inflammatory myopathy of children, is rare, with an estimated incidence of 2-4 in 1 million children. Given the…
  • Abstract Number: 1793 • ACR Convergence 2021

    Impact of Gender and Age on Psoriatic Arthritis Patient Profiles at Golimumab Initiation and 12-Month Outcomes

    Arthur Karasik1, Isabelle Fortin2, Proton Rahman3, Regan Arendse4, Emmanouil Rampakakis5, Odalis Asin-Milan6, Allen Lehman6, Francois Nantel7 and Meagan Rachich6, 1Arthur Karasik Medicine Professional Corporation, Toronto, ON, Canada, 2CREQ, Rimouski, QC, Canada, 3Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, 4University of Saskatchewan, Saskatoon, SK, Canada, 5JSS Medical Research, Montréal, QC, Canada, 6Janssen Inc., Toronto, ON, Canada, 7., Montréal, QC, Canada

    Background/Purpose: Gender and age have been previously identified as independent predictors of response to anti-TNFs. The aim of this analysis was to compare, between genders…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology